STOCK TITAN

Vanguard disaggregates holdings; reports 0 shares in Biogen (NASDAQ: BIIB)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Biogen Inc. — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting zero shares of Biogen common stock and 0% beneficial ownership following an internal realignment.

The filing states certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538, effective after the January 12, 2026 realignment. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What did The Vanguard Group report for BIIB in Amendment No. 13?

Vanguard reported 0 shares and 0% beneficial ownership of BIIB common stock. The amendment reflects an internal realignment that disaggregated certain subsidiary holdings under SEC Release No. 34-39538 on January 12, 2026.

Does Amendment No. 13 change who controls Biogen shares for BIIB?

No change to voting or dispositive power is reported; all entries show 0 for vote and disposition. The filing explains subsidiaries will report separately; no single Vanguard entity claims control in this amendment.

Why did Vanguard file this Schedule 13G/A amendment for BIIB?

The amendment records an internal realignment dated January 12, 2026 under SEC Release No. 34-39538. It disaggregates beneficial ownership so former Vanguard subsidiaries report holdings separately rather than under The Vanguard Group, Inc.

Who signed the BIIB Schedule 13G/A amendment for Vanguard?

Ashley Grim, Head of Global Fund Administration, signed the filing on 03/26/2026. The signature block appears at the end of the amendment and provides the filer’s title and date.

Does the amendment identify any third parties with rights to BIIB dividends or proceeds?

The filing states Vanguard, including managed accounts, has the right to receive or direct dividends/proceeds, and no other single person holds more than 5%. It notes shareholder listings for investment companies or benefit plans are not required.
Biogen Inc

NASDAQ:BIIB

View BIIB Stock Overview

BIIB Rankings

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

27.76B
146.32M
Drug Manufacturers - General
Biological Products, (no Diagnostic Substances)
Link
United States
CAMBRIDGE